Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 20, 2008

View Archived Issues

Further phase III data on golimumab in psoriatic and rheumatoid arthritis presented

Novel treatment options for cancer covered in recent patent literature

Recent Wyeth patent reports treatments to prevent opioid-induced adverse effects

Novel treatment options for iron overloading divulged in recent Xenon patents

Xytis will begin phase I trial with XY-4083 in early 2009

Interim results of READ 2, RESOLVE and SUSTAIN trials reveal benefits with ranibizumab

InteRNA and Cenix sign research agreement for miRNA drug discovery in cancer

Oxford BioMedica presents update on clinical development of its gene-based therapies

Potent antihyperalgesia and good safety profile with novel delta opioid receptor agonist

Antisoma presents update on clinical development of its key oncolytic products

Promising procognitive effects of Abbott's new 5-HT6 receptor antagonist

NitroMed and Archemix announce merger agreement

Ziopharm presents positive data from palifosfamide studies

GP Pharm releases data from preclinical studies of Sarcodoxome

PAION successfully completes phase I sedative/anesthetic CNS-7056 study

Accera to launch Axona for the dietary management of AD in 2009

Agile's lead product, AG-200-15, moves into pivotal phase III trials

Metabolex presents results from phase II MBX-8025 trial

Novagali withdraws EMEA marketing authorization application for Vekacia

Phase I trials confirm excellent tolerance of GFT-505 in healthy volunteers

Xenome and Flinders collaborate to develop peptides to treat acute pancreatitis

Phase II IMC-A12 study for HER2-expressing breast cancer starts enrollment

NovaBay initiates enrollment in phase II study of NVC-422 for CAUTI

Antiviral activity seen with PEG-Interferon lambda in phase I HCV study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...